Skip to main content
. Author manuscript; available in PMC: 2022 Apr 10.
Published in final edited form as: Cancer Lett. 2021 Jan 22;503:91–102. doi: 10.1016/j.canlet.2021.01.015

Figure 6. Genetic deletion of MUC4 induces sensitivity to gemcitabine in PDAC cells.

Figure 6.

A. Cytotoxicity assay of gemcitabine in T3M4 WT, WT-MUC4KO (4D3), T3M4 SC and SC-MUC4KO (5D10) cells (mean ± SD, n=5). B and C qRT-PCR analysis of mRNA expression of hENT1 and hCNT3 in T3M4 WT, WT-MUC4KO (4D3), T3M4 SC and SC-MUC4KO (5D10) cells (mean ± SD, n=3). D and E Western blotting of protein expression of hENT1 and hCNT3 in T3M4 WT, WT-MUC4KO (3B4 and 4D3), SC, SC-MUC4KO (1E11 and 5D10). β-actin acts as a loading control. Immunohistochemical analysis of hENT1 (F and G) and hCNT3 (H and I) in T3M4 WT, WT-MUC4KO (4D3), T3M4 SC, and SC-MUC4KO (5D10) cells implanted xenograft tumors (mean ± SD, n=5).